跳至主要内容
临床试验/CTRI/2021/10/037493
CTRI/2021/10/037493已完成未知

EFFECTIVENESS OF N-ACETYL CYSTEINE AS AN ADD ON THERAPY IN NEGATIVE AND COGNITIVE SYMPTOMS OF SCHIZOPHRENIA, A PLACEBO CONTROLLED DOUBLE BLINDED 24 WEEKS FOLLOW-UP RANDOMIZED CONTROL TRIA

Dr Sharon Narula0 个研究点目标入组 70 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
70

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • All patients coming for treatment at the OPD and IPD of the
  • Department of Psychiatry fulfilling the following are
  • a) Patients with Schizophrenia according to ICD10-
  • DCR (International Classification of Diseases 10â??
  • Diagnostic Criteria for Research).
  • b) Aged between 18 to 65 years of either sex
  • c) Patients on treatment with Olanzapine on an adequate
  • d) With Informed consent from the Legally Authorized

排除标准

  • Patients with any one of the following are excluded from the
  • a) With a history of head trauma or seizure disorder or
  • neurodevelopmental delay
  • b) On NAC as a medication
  • c) Who are allergic to NAC or any component of it
  • d) Who are taking Selective Serotonin Reuptake
  • Inhibitors (SSRIs)
  • e) Pregnant or lactating females

研究者

发起方
Dr Sharon Narula

相似试验